We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Technological advances and other innovations have made it feasible for developing countries to establish biobanks — repositories of human biological samples linked with data from individuals, write S. K. Sgaier and colleagues in Science.

They see the likely emergence of a global consortium of biobanks as offering "accessible and affordable studies in diverse populations" permitting "imaginative search for common and rare genetic and other biological correlates of global diseases".

One technological development is the use of dried blood spots (DBS) instead of costly serum samples that must be kept cold continuously.

And in Indian household surveys last year, only five per cent of people refused to give dried blood samples, compared with refusal rates of nearly 40 per cent for serum samples.

The authors highlight the importance of linking samples with improved disease and mortality surveillance systems, citing India's 'Million Death Study' — an initiative to examine the underlying risk factors of disease in the country — as a pioneering example of data collection.

Sgaier and colleagues are investigating the issues involved in building a national DBS-based biobank in India, which they estimate would cost US$10 per person, compared to US$240 per person for the serum-based UK Biobank.

Link to full article in Science

Related topics